Syndax Pharmaceuticals, Inc. Share Price
NASDAQ: SNDX | Small CapSyndax Pharmaceuticals, Inc. Stock Performance
Open $20.07 | Prev. Close $19.71 | Circuit Range N/A |
Day Range $19.84 - $20.39 | Year Range $12.19 - $25.58 | Volume 63,274 |
Average Traded $20.10 |
Syndax Pharmaceuticals, Inc. Share Price Today
As of 10 August 2026, Syndax Pharmaceuticals, Inc.'s share price is $20.41. The stock opened at $20.07, compared to its previous close of $19.71. During today's trading session, Syndax Pharmaceuticals, Inc.'s share price traded between $19.84 and $20.39, with an average price of $20.11. Over the past 52 weeks, the stock has recorded a high of $25.58 and a low of $12.19. In terms of performance, Syndax Pharmaceuticals, Inc.'s share price has declined by 6.05% over the last six months and is up 25.03% on a year-on-year basis.
Syndax Pharmaceuticals, Inc. Share Price Chart
Syndax Pharmaceuticals, Inc. Stock Fundamentals & Key Indicators
Market Cap $1.77B | PE Ratio (TTM) -6.20 | Dividend Yield N/A |
EPS (TTM) $-3.29 | Revenue (TTM) $172.35M | Return On Equity (TTM) -441.62% |
Profit Margin -165.60% | Debt to Equity 1.86 | Quarterly Earnings Growth YoY 27.83% |
Syndax Pharmaceuticals, Inc. Quarterly Profit & Loss
All figures in USD
Syndax Pharmaceuticals, Inc. Annual Profit & Loss
All figures in USD
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Syndax Pharmaceuticals, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $19.09 | $20.41 | +7.20% |
Jul 2026 | $22.06 | $19.04 | -12.84% |
Jun 2026 | $19.30 | $21.84 | +11.49% |
May 2026 | $20.98 | $19.59 | -8.82% |
Apr 2026 | $23.85 | $21.48 | -8.07% |
Mar 2026 | $21.63 | $23.37 | +7.60% |
Feb 2026 | $20.45 | $21.72 | +6.84% |
Jan 2026 | $21.18 | $20.33 | -3.28% |
Dec 2025 | $19.71 | $21.02 | +5.95% |
Nov 2025 | $13.67 | $19.84 | +44.82% |
Oct 2025 | $15.74 | $13.70 | -10.95% |
Sep 2025 | $16.65 | $15.38 | -5.73% |
SNDX Share Price FAQs
What is Syndax Pharmaceuticals, Inc. share price today?
What is the 52 week high and 52 week low of Syndax Pharmaceuticals, Inc. stock?
What is SNDX's market capitalisation today?
What is SNDX's net income for the last quarter?
What is the 5 year returns of SNDX?
What is the high & low stock price of SNDX today?
Can I buy SNDX shares in India?